LJLakshmi Jayashankar

Lakshmi Jayashankar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lakshmi Jayashankar has a total of 157 co-authors. Here are the top co-authors by number of shared publications:

  • Franco Scinicariello

    Division of Toxicology and Environmental Medicine, Centers of Disease Control and Prevention, Agency for Toxic Substances and Disease Registry , Atlanta, GA 30341

    5 shared publications
  • Suryaprakash Sambhara

    Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA

    5 shared publications
  • Julie Vergara

    Infectious Disease Research Institute, Seattle, WA 98102 USA

    3 shared publications
  • Mary Hoelscher

    National Center for Immunization and Respiratory Diseases, Influenza Division, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Mail Stop G47, 1600 Clifton Road, Atlanta, GA 30333, USA

    3 shared publications
  • Roberta Attanasio

    Department of Biology, Georgia State University , Atlanta, GA 30303

    3 shared publications
  • Roberta Attanasio

    Department of Biology, Georgia State University, Atlanta, GA 30303, USA

    3 shared publications

Latest Publications

  • Eliminating perinatal HIV in the United States

    by Devasena Gnanashanmugam, Natella Rakhmanina, Keith W. Crawford, Steven Nesheim, Theodore Ruel, Guthrie S. Birkhead, Rana Chakraborty, Robert Lawrence, Patrick Jean-Philippe, Lakshmi Jayashankar, et al.

    In 2015, only 53 infants born in the United States acquired HIV, the lowest recorded number of perinatal HIV infections. Recognizing this significant achievement, we must acknowledge that the United States has not yet reached the goal of eliminating perinatal HIV transmission. This manuscript describes different approaches to perinatal HIV preventive services among five states and the District of Columbia as case studies. Continuous focus on improving identification, surveillance and prevention of HIV infection in pregnant women and their infants is necessary to reach the goal of eliminating perinatal HIV transmission in the United States.


  • Open Access

    The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

    by Rhea N. Coler, Tracey A. Day, Ruth Ellis, Franco M. Piazza, Anna Marie Beckmann, Julie Vergara, Tom Rolf, Lenette Lu, Galit Alter, David Hokey, et al.

    Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of improved TB vaccines that boost or replace BCG is a major global health goal. ID93 + GLA-SE is a fusion protein TB vaccine candidate combined with the Toll-like Receptor 4 agonist adjuvant, GLA-SE. We conducted a phase 1, randomized, double-blind, dose-escalation clinical trial to evaluate two dose levels of the ID93 antigen, administered intramuscularly alone or in combination with two dose levels of the GLA-SE adjuvant, in 60 BCG-naive, QuantiFERON-negative, healthy adults in the US (ClinicalTrials.gov identifier: NCT01599897). When administered as 3 injections, 28 days apart, all dose levels of ID93 alone and ID93 + GLA-SE demonstrated an acceptable safety profile. All regimens elicited vaccine-specific humoral and cellular responses. Compared with ID93 alone, vaccination with ID93 + GLA-SE elicited higher titers of ID93-specific antibodies, a preferential increase in IgG1 and IgG3 subclasses, and a multifaceted Fc-mediated effector function response. The addition of GLA-SE also enhanced the magnitude and polyfunctional cytokine profile of CD4+ T cells. The data demonstrate an acceptable safety profile and indicate that the GLA-SE adjuvant drives a functional humoral and T-helper 1 type cellular response.


  • Tuberculous meningitis: a roadmap for advancing basic and translational research

    by on behalf of the NIH Tuberculous Meningitis Writing Group, Sanjay K. Jain, David M. Tobin, Elizabeth W. Tucker, Vishwanath Venketaraman, Alvaro A. Ordonez, Lakshmi Jayashankar, Omar K. Siddiqi, Dima A. Hammoud, Nemani V. Prasadarao, et al.


  • Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial

    by Adam Penn-Nicholson, Michele Tameris, Erica Smit, Tracey A Day, Munyaradzi Musvosvi, Lakshmi Jayashankar, Julie Vergara, Simbarashe Mabwe, Nicole Bilek, Hendrik Geldenhuys, et al.


  • HIV birth testing and linkage to care for HIV-infected infants

    by Patrick Jean-Philippe, Hans Spiegel, Devasena Gnanashanmugam, Joseph Fitzgibbon, Patricia D'SOuza, Keith W. Crawford, Lakshmi Jayashankar, Melanie C. Bacon, Shaffiq M. Essajee, Grace M. Aldrovandi, et al.

    On 5–6 May 2016, the division of AIDS of the National Institute of Allergy and Infectious Diseases convened a workshop on ‘HIV Birth Testing and Linkage to Care for HIV Infected Infants.’ The goal of the workshop was to evaluate birth testing for early infant diagnosis (EID) of HIV, delineate technological resources for advancing a point-of-care (POC) HIV test implementable at birth and chart out the implementation hurdles for initiating early antiretroviral therapy to HIV-infected infants diagnosed at birth. The workshop addressed research and regulatory needs involved in the optimization of POC EID testing and challenges associated with implementation of EID, focusing on testing at birth. Scientific gaps and areas of intervention to accelerate and scale-up EID initiatives and birth testing were identified. These include discussion of the evidence supporting an early mortality peak among HIV-infected infant and justifying a role for birth HIV testing, including POC testing; evaluation of the current POC EID technology pipeline and test performance characteristics required for effective programmatic uptake; mathematical modeling of different testing scenarios and solutions with inclusion of birth testing; the adoption of setting-specific EID testing algorithms to achieve efficient linkage to care including early antiretroviral therapy initiation; the development of appropriate quality assurance programs to ensure accuracy of test results and enable sustainability of the testing program. Addressing these gaps and answering these challenges will be important in helping improve outcomes for HIV-infected infants and accelerate achieving the Joint United Nations Program for HIV and AIDS 90–90–90 targets in children.


  • Open Access

    Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination

    by Lakshmi Jayashankar, Richard Hafner

    Tuberculosis remains a global health threat of alarming proportions, resulting in 1.5 million deaths worldwide. The only available licensed vaccine, BCG, does not confer lifelong protection against active TB. To date, development of an effective vaccine against TB has proven to be elusive, and devising newer approaches for improved vaccination outcomes is an essential goal. Insights gained over the last several years have revealed multiple mechanisms of immune manipulation by Mtb in infected macrophages and dendritic cells that support disease progression and block development of protective immunity. This review provides an assessment of the known immunoregulatory mechanisms altered by Mtb, and how new interventions may reverse these effects. Examples include blocking of inhibitory immune cell co-receptor checkpoints (e.g. PD-1). Conversely, immune mechanisms that strengthen immune cell effector functions may be enhanced by interventions, including stimulatory immune cell co-receptors (e.g., OX40). Modification of the activity of key cell “immunometabolism” signaling pathway molecules, including mTOR, GSK3β, wnt/β-catenin, AMPK and sirtuins, related epigenetic changes, and preventing induction of immune regulatory cells (e.g., Tregs, MDSCs) are powerful new approaches to improve vaccine responses. Interventions to favorably modulate these components have been studied primarily in oncology to induce efficient anti-tumor immune responses, often by potentiation of cancer vaccines. These agents include antibodies and a rapidly increasing number of small molecule drug classes that have contributed to the dramatic immune-based advances in treatment of cancer and other diseases. Because immune responses to malignancies and to Mtb share many similar mechanisms, studies to improve TB vaccine responses using interventions based on “immuno-oncology” are needed to guide possible repurposing. Understanding regulation of immune cell functions appropriated by Mtb to promote the imbalance between protective and pathogenic immune responses may guide development of innovative drug-based adjunct approaches to substantially enhance the clinical efficacy of TB vaccines.


  • Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults

    by Marilia Santini-Oliveira, Rhea N. Coler, Juçara Parra, Valdilea Veloso, Lakshmi Jayashankar, Patricia M. Pinto, Marcia A. Ciol, Robert Bergquist, Steven G. Reed, Miriam Tendler


  • Open Access

    From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH‐F3+GLA‐SE

    by Rhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, Jeffery Guderian, Lakshmi Jayashankar, Julie Vergara, Tom Rolf, Ayesha Misquith, John D Laurance, Vanitha S Raman, et al.

    Key antigens of Leishmania species identified in the context of host responses in Leishmania‐exposed individuals from disease‐endemic areas were prioritized for the development of a subunit vaccine against visceral leishmaniasis (VL), the most deadly form of leishmaniasis. Two Leishmania proteins—nucleoside hydrolase and a sterol 24‐c‐methyltransferase, each of which are protective in animal models of VL when properly adjuvanted— were produced as a single recombinant fusion protein NS (LEISH‐F3) for ease of antigen production and broad coverage of a heterogeneous major histocompatibility complex population. When formulated with glucopyranosyl lipid A‐stable oil‐in‐water nanoemulsion (GLA‐SE), a Toll‐like receptor 4 TH1 (T helper 1) promoting nanoemulsion adjuvant, the LEISH‐F3 polyprotein induced potent protection against both L. donovani and L. infantum in mice, measured as significant reductions in liver parasite burdens. A robust immune response to each component of the vaccine with polyfunctional CD4 TH1 cell responses characterized by production of antigen‐specific interferon‐γ, tumor necrosis factor and interleukin‐2 (IL‐2), and low levels of IL‐5 and IL‐10 was induced in immunized mice. We also demonstrate that CD4 T cells, but not CD8 T cells, are sufficient for protection against L. donovani infection in immunized mice. Based on the sum of preclinical data, we prepared GMP materials and performed a phase 1 clinical study with LEISH‐F3+GLA‐SE in healthy, uninfected adults in the United States. The vaccine candidate was shown to be safe and induced a strong antigen‐specific immune response, as evidenced by cytokine and immunoglobulin subclass data. These data provide a strong rationale for additional trials in Leishmania‐endemic countries in populations vulnerable to VL.


  • Open Access

    5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication

    by Priya Ranjan, Lakshmi Jayashankar, Varough Deyde, Hui Zeng, William G Davis, Melissa B Pearce, John B Bowzard, Mary A Hoelscher, Victoria Jeisy-Scott, Mayim E Wiens, et al.

    Background: Emergence of drug-resistant strains of influenza viruses, including avian H5N1 with pandemic potential, 1918 and 2009 A/H1N1 pandemic viruses to currently used antiviral agents, neuraminidase inhibitors and M2 Ion channel blockers, underscores the importance of developing novel antiviral strategies. Activation of innate immune pathogen sensor Retinoic Acid Inducible Gene-I (RIG-I) has recently been shown to induce antiviral state. Results: In the present investigation, using real time RT-PCR, immunofluorescence, immunoblot, and plaque assay we show that 5'PPP-containing single stranded RNA (5'PPP-RNA), a ligand for the intracytoplasmic RNA sensor, RIG-I can be used as a prophylactic agent against known drug-resistant avian H5N1 and pandemic influenza viruses. 5'PPP-RNA treatment of human lung epithelial cells inhibited replication of drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza viruses in a RIG-I and type 1 interferon dependant manner. Additionally, 5'PPP-RNA treatment also inhibited 2009 H1N1 viral replication in vivo in mice. Conclusions: Our findings suggest that 5'PPP-RNA mediated activation of RIG-I can suppress replication of influenza viruses irrespective of their genetic make-up, pathogenicity, and drug-sensitivity status.


  • Vaccines against epidemic and pandemic influenza

    by Mary Hoelscher, Shivaprakash Gangappa, Weimin Zhong, Lakshmi Jayashankar, Suryaprakash Sambhara, Bs Mba, Dvm, Ph D

    Background: Preventative vaccination is the most effective way to control epidemic and, perhaps, pandemic influenza viral infections. However, the immunogenicity and efficacy of influenza vaccines against epidemic strains are suboptimal among older adults. The risk of serious complications from influenza viral infection is compounded by co-morbid conditions among older adults. Furthermore, despite annual influenza vaccination campaigns, the vaccination rates in high risk populations range from 60.5 – 79.2% only 1. State-specific influenza vaccination coverage among adults aged > or = 18 years – United States, 2003–04 and 2005–06 influenza seasons. MMWR Morb Mortal Wkly Rep 2007;56(37):953-9 [PubMed] View all references . In addition, H5N1 avian influenza viruses have the potential to cause a pandemic. However, H5N1 vaccines currently licensed in the US are poorly immunogenic in high doses in the absence of an adjuvant even in healthy adults. Objectives: In this review, we address the current status of vaccines against epidemic and avian influenza viruses of pandemic potential. Methods: We have limited the review to the discussion of technologies and strategies that have progressed to human clinical trials and/or licensure for seasonal and pandemic influenza. Results/conclusion: Improving the immunogenicity of vaccines against avian influenza viruses, as well as aggressive programs to vaccinate high risk populations against seasonal and pandemic influenza, are crucial for our public health efforts in minimizing the impact of influenza epidemics or pandemics.